Aarti Drugs Limited has informed the Exchange about General Updates - Re-appointment of Cost Auditor and Internal Auditor
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Drugs Limited reported audited standalone total income of Rs 15,844 lakhs and consolidated total income of Rs 2,40,339 lakhs for FY 2025-26. Consolidated profit before tax stood at Rs 21,090 lakhs with EPS of Rs 21.36. The company re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY 2026-27 and M/s Raman S. Shah & Co. as Internal Auditor for 3 years starting April 1, 2026. The Risk Management Committee was reconstituted with the addition of Shri Narendra J. Salvi as a member. Statutory auditors Gokhale & Sathe issued an un-modified (clean) audit opinion. The board meeting lasted from 2:50 PM to 4:40 PM on May 15, 2026.
The clean audit opinion and strong financial performance with consolidated revenue over Rs 2,400 crore are positive signals for investors. The routine re-appointment of auditors indicates stable governance. No major red flags or adverse changes for shareholders.